Boardroom Alpha
Meeting calendar
MQ · Annual meeting · Wednesday, June 10, 2026

Marqeta Inc

4 nominees · 5 ballot items.

Election of four Class II directors; ratification of KPMG LLP as independent auditor; approval of a 1-for-4 reverse stock split and related reduction of authorized shares; approval of an amendment to provide officer exculpation as permitted by Delaware law; and a non-binding advisory vote on named executive officer compensation.

Market cap
$1.9B
1Y TSR
-30.8%
Board grade
C-
Record date
Apr 15, 2026
Filing
DEF 14A
Meeting concluded · Jun 10, 2026

Follow how the vote landed and what changed on Marqeta Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot5

  1. 1

    Election of the four Class II directors

    ManagementBoard: FOR

    Elect four Class II director nominees (Najuma Atkinson, Martha Cummings, Judson (Jud) Linville, and Michael (Mike) Milotich) to hold office until the 2029 annual meeting.

  2. 2

    Ratification of appointment of independent registered public accounting firm (KPMG LLP

    ManagementBoard: FOR

    Ratify the Audit Committee’s appointment of KPMG LLP as Marqeta’s independent registered public accounting firm for fiscal year ending December 31, 2026.

  3. 3

    Approval of a reverse stock split and related reduction of our authorized Common Stock

    ManagementBoard: FOR

    Approve an amendment to the Certificate of Incorporation to permit a 1-for-4 reverse stock split of Class A, Class B and Preferred Stock and a proportionate reduction in authorized shares, with implementation at the discretion of the CEO and CFO in consultation with the Board.

    More detail

    This management proposal asks stockholders to authorize an amendment to the Company’s Certificate of Incorporation enabling a 1-for-4 reverse stock split of Class A, Class B and Preferred shares and a proportionate reduction in authorized shares, with implementation left to the CEO and CFO in consultation with the Board within one year of approval. Management frames the primary rationale as reducing the number of outstanding shares to increase reported earnings (or loss) per share, thereby improving the meaningfulness of per-share metrics; it also cites secondary benefits including potential improvements to marketability, trading costs, and administrative/listing savings. Implementation would not change percentage ownership except for cashing out fractional shares and would be effective on filing a Certificate of Amendment; the Board reserves discretion and will consider market conditions, company performance, and likely effects on market price before acting. Key risks disclosed include potential failure of price to increase proportionately, reduced liquidity, increased odd-lot trading costs, and the possibility that market capitalization could decline after the split; management also notes tax and procedural mechanics (cash payments for fractional interests and no appraisal rights under Delaware law). The proposal includes technical adjustments to outstanding equity awards, reserved shares, and plan share counts to reflect the reverse split ratio. The Board recommends FOR, arguing the combination of reduced share count, improved per-share metrics, and potential market/listing benefits are in stockholders’ interests. For holders evaluating the proposal, important governance considerations include the Board/management’s unilateral authority to implement the split within a year, the remedy for fractional shares (cash), the effects on liquidity and trading dynamics, and the lack of a required reduction in authorized shares absent stockholder approval (which this proposal also authorizes). Overall, the economic benefit to long-term stockholders depends on whether the market treats the reverse split as a neutral structural change or as a signal that affects liquidity and investor demand; the risk/benefit calculus hinges on post-split trading behavior and the Board’s timing decision.

  4. 4

    Approval of amendment to Certificate of Incorporation to provide for officer exculpation as permitted by Delaware law

    ManagementBoard: FOR

    Approve an amendment to the Certificate of Incorporation to add Article XI limiting certain officers' personal monetary liability for breaches of the duty of care to the fullest extent permitted by Delaware law, subject to statutory exceptions.

    More detail

    This management proposal asks stockholders to approve an amendment to the Certificate of Incorporation to add Article XI permitting officer exculpation to the fullest extent allowed by the Delaware General Corporation Law. Management and the Board argue the amendment remedies an historical inconsistency between the treatment of officers and directors, aligns Marqeta with peer practices following the 2022 DGCL amendment, and helps protect the Company from nuisance litigation and resulting higher D&O insurance costs. The Board also emphasizes recruitment and retention benefits—arguing that prospective or current officer candidates may be deterred from serving without comparable exculpatory protections—while stating the amendment is prospective and not proposed in anticipation of any specific litigation. The amendment expressly excludes breaches of the duty of loyalty, acts not in good faith, intentional misconduct or knowing violations of law, and transactions conferring improper personal benefit, and does not affect derivative claims brought by or in the right of the Company. The proposed change requires a majority vote and would become effective upon filing with the Delaware Secretary of State, but the Board retains discretion to abandon the amendment prior to effectiveness. From a governance perspective, investors should weigh the reduced personal monetary exposure for officers against potential accountability concerns, noting that other protections (e.g., liability for loyalty breaches, intentional misconduct, and derivative suits) remain. The Board’s recommendation for FOR rests on balancing stockholder interests in accountability with the practical needs to attract senior talent and limit company costs, but stockholders should consider the implications for officer incentives and oversight when evaluating the proposal.

  5. 5

    Advisory vote on executive compensation (Say-on-Pay

    ManagementBoard: FOR

    Non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement, including the Compensation Discussion & Analysis and compensation tables.

    More detail

    This advisory (non-binding) proposal asks stockholders to approve, on an annual basis, the compensation paid to the Company’s named executive officers as disclosed, including the Compensation Discussion & Analysis and compensation tables. Management and the Compensation Committee state their program is designed to recruit, retain, and align executive pay with long-term stockholder value through a mix of base salary, performance-based cash incentives, and equity (RSUs and PSUs), and that pay decisions incorporated independent consultant benchmarking and targeted performance metrics (revenue growth, gross profit, adjusted EBITDA) for 2025. While non-binding, the Board says it will consider the vote outcome when setting future pay; given the 98% support in 2025, management presents this as evidence of stockholder alignment with its approach. For sophisticated evaluation, key issues include the high proportion of performance-based compensation, the design of short- and long-term metrics (one-year PSUs in 2025 with a plan to lengthen over time), retention/promotional awards tied to CEO transition, and the potential dilution and governance implications of large time-based and promotion-related equity grants. Stockholders should consider whether the disclosed pay-for-performance linkages, disclosure of adjustments and retention awards, and the committee’s use of external benchmarking adequately manage agency risk and incentivize sustainable long-term value creation.

Director elections

Nominees on the ballot4

Independent
Tenure on this board
5.1 yrs
Also a director at
Alkami Technology Inc (ALKT)
Ownership

Top institutional holders10

Latest 13F quarter
1PRICE T ROWE ASSOCIATES INC /MD/49.7%52,720,878$215M
2T. Rowe Price Investment Management, Inc.23.6%24,971,778$102M
3VANGUARD PORTFOLIO MANAGEMENT LLC16.0%16,930,131$69M
4VANGUARD CAPITAL MANAGEMENT LLC15.6%16,529,577$67M
5BlackRock, Inc.12.0%12,766,654$52M
6RENAISSANCE TECHNOLOGIES LLC10.9%11,580,288$47M
7BlackRock, Inc.10.2%10,793,866$44M
8STATE STREET CORP8.7%9,235,084$38M
9DIMENSIONAL FUND ADVISORS LP7.9%8,323,979$34M
10GEODE CAPITAL MANAGEMENT, LLC7.6%8,052,560$33M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Marqeta Inc 2026 annual meeting?
Marqeta Inc (MQ) holds its 2026 annual shareholder meeting on Wednesday, June 10, 2026.
What is the record date for the Marqeta Inc 2026 meeting?
The record date for the Marqeta Inc 2026 meeting is Wednesday, April 15, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Marqeta Inc's 2026 meeting?
The board is presenting 4 director nominees at the Marqeta Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Marqeta Inc 2026 meeting?
Shareholders will vote on 5 proposals at the Marqeta Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer